Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00681889 · ClinicalTrials.gov registry record · Phase 1
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
A Phase 1 study, sponsored by Reza Dana, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00681889: Completed Phase 1 study, sponsored by Reza Dana, MD.
NCT00681889 is a Phase 1 study that has completed, run by Reza Dana, MD. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00681889, a Phase 1 study, has completed, sponsored by Reza Dana, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.
Primary Outcome
Incidence and severity of ocular adverse events, as identified by eye examination and visual acuity testing
Interventions
- DRUG Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
What the finished NCT00681889 record still lists
NCT00681889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00681889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00681889 about?
NCT00681889 is a clinical study titled "Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)". The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.
What is the current status of trial NCT00681889?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-04. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00681889?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00681889?
This trial is sponsored by Reza Dana, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00681889's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia